Search Results

41 - 50 of 89 items :

  • pharmacokinetics x
  • Internal Medicine x
Clear All
Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab

chemotherapy plus trastuzumab plus bevacizumab. Available at http://clinicaltrials.gov/ct2/show/NCT00625898?term=BETH&rank=1 16. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008; 62: 779-86. 17. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J

Open access
Management of cutaneous side effects of cetuximab therapy with vitamin K1 crème

-602. Ciardiello F, Cervantes A, Vega-Villegas ME, Casado E, Rodriguez-Braun E, Martinelli E., et al. Optimal dose for an every 2 week (q2w) cetuximab (C) regimen in patients (pts) metastatic colorectal cancer (mCRC): a phase I safety, pharmacokinetics(PK) and pharmacodynamics (PD) study of weekly (q1w) add q2w schedules. [Abstract]. Eur J Cancer 2007; 5(4): 247. Pfeiffer P, Bjerregaard JK, Qvortrup C, Jensen BV, Yilmaz M, Nielsen D. Simplification of cetuximab (Cet) administration: double dose of every second week as a 60 minute infusion. J Clin

Open access
Gender and Contractile Functions of Slow and Fast Skeletal Muscles in Streptozotocin Induced Diabetic Sprague Dawley Rats

.1155/2010/931903, 2010. 14. Eng CM, Smallwood LH, Rainiero MP, Lahey M, Ward SR, Lieber RL. Scaling of muscle architecture and fiber types in the rat hindlimb. J Exp Biol 211: 2336-2345, 2008. 15. Hu N, Xie S, Liu L et al. Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats. Drug Metab Dispos 39: 419-425, 2011. 16. Dupouy VM, Ferre PJ, Uro-Coste E, Lefebvre HP. Time course of COX-1 and COX-2 expression during ischemia-reperfusion in rat skeletal muscle. J

Open access
Current status of in vitro and in vivo antifungal activities of posaconazole

posaconazole in experimental models of invasive fungal infections. Mycoses 2006;49:S7-16. 14. Petraitiene R, Petraitis V, Groll AH, Sein T, Piscitelli S, Candelario M, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: Correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001;45:857-69. 15. Graybill JR, Hernandez S, Bocanegra R, Najvar LK. Antifungal therapy of murine Aspergillus terreus infection. Antimicrob Agents

Open access
Comparison of continuous local anaesthetic and systemic pain treatment after axillary lymphadenectomy in breast carcinoma patients – a prospective randomized study

-42. 36. Stratford AF, Zoutman DE, Davidson JS. Effect of lidocaine and epinephrine on Staphylococcus aureus in a guinea pig model of surgical wound infection. Plast Reconstr Surg 2002; 110: 1275-9. 37. Parr AM, Zoutman DE, Davidson JS. Antimicrobial activity of lidocaine against bacteria associated with nosocomial wound infection. Ann Plast Surg 1999; 43: 239-45. 38. Mather LE, Copeland SE, Ladd LA. Acute toxicity of local anesthetics: underlying pharmacokinetic and pharmacodynamic concepts. Reg Anesth Pain Med 2005; 30: 553-66.

Open access
Treatment outcomes and survival in patients with primary central nervous system lymphomas treated between 1995 and 2010 – a single centre report

M, et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102: 673-7. 28. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz MJ, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23: 5034-43. 29. Uhm JE, Kim KH, Yi SY, Chang MH, Park KW, Kong DS, et al. A

Open access
Tumor size and effectiveness of electrochemotherapy

; 9: 22-25. 31. Alberts DS, Chen HS, Liu R, Himmelstein KJ, Mayersohn M, Perrier D, et al. Bleomycin pharmacokinetics in man. I. Intravenous administration. Cancer Chemother Pharmacol 1978; 1: 177-181. 32. Sersa G, Jarm T, Kotnik T, Coer A, Podkrajsek M, Sentjurc M, et al. Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer 2008; 98: 388-398. 33. Sersa G, Krzic M, Sentjurc M, Ivanusa T, Beravs K, Kotnik V, et al. Reduced blood flow and oxygenation

Open access
Are Obese Women a Risk Group for Vitamin B12 and Folic Acid Deficiencies ?

. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49: 71-87, 2010. 24. Zhou SS, Li D, Chen NN, Zhou Y. Vitamin paradox in obesity: Deficiency or excess? World J Diabetes 6: 1158-1167, 2015. 25. Bird JK, Ronnenberg AG, Choi SW, Du F, Mason JB, Liu Z. Obesity is associated with increased red blood cell folate despite lower dietary intakes and serum concentrations. J Nutr 145: 79-86, 2015. 26. Pfeiffer CM, Sternberg MR, Fazili Z et al. Folate status and concentrations of serum folate forms in the US population

Open access
Association between SLC19A1 gene polymorphism and high dose methotrexate toxicity in childhood acute lymphoblastic leukaemia and non Hodgkin malignant lymphoma: introducing a haplotype based approach

haplotype for SLC19A1 rs7499, rs1051266, rs2838956 and rs3788200 with MTX gastrointestinal toxicity was established. 38 The results of the haplotype based analysis indicate, that other polymorphisms that are in linkage disequilibrium with rs1051266 and rs1131596, may impact the functioning of SLC19A1 via, for example, alterations in SLC19A1 splicing. 39 , 40 As well, other genes coding for proteins that are involved in the transport and metabolism of MTX can also impact pharmacokinetics and the occurrence of MTX-induced AE, such as SLCO1B1 SNPs that are

Open access
Timing of anticoagulation for portal vein thrombosis in liver cirrhosis: An Italian internist’s perspective

favorable data on the DOACs but they are not licensed for this indication yet. However, it should be remembered that rivaroxaban is contraindicated in patients with advanced cirrhosis (Child class B and C), after a pharmacokinetic study showed increased rivaroxaban concentrations in patients with moderate hepatic impairment;[ 32 , 33 ] while apixaban has the highest percentage of hepatic metabolism (up to 73%) and therefore should be used with caution in patients with mild or moderate liver impairment (Child class A and B), it is not recommended in patients with severe

Open access